Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end. A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor. Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an ave